SPOTLIGHT: GSK expands pact with Galapagos


Galapagos has gained a €4.4 million equity investment from GlaxoSmithKline as the two companies expand an alliance on osteoarthritis. GSK will bring a drug discovery program against a selected GSK target into the alliance. Within this additional program, Galapagos will progress a disease-modifying drug toward completion of clinical Phase IIa, at which point GSK's global research and development organization will be responsible for the late-stage development, production and marketing of the drug. Release | Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.